Guggenheim Rates Natera (NTRA) buy, $290 Price Target

Guggenheim maintains its buy rating on Natera, setting a price target of $290, a 8.60% upside from the current price.

By EarningsIQ Research Desk · Published Jun 29, 2026, 11:01 AM EDT · Updated Jul 1, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Natera, Inc. ($NTRA) "buy" with a $290 price target on June 29, 2026.

Since the rating, $NTRA is up 4.2% after 1 week, down 6.8% after 1 month and up 44.5% to date (from the $272.31 close on Jun 29, 2026).

NTRA Natera, Inc.

$393.44 +71.93% year to date

Daily close · Oct 16, 2026

Key Points

Guggenheim reiterated its buy rating on Natera, Inc. with a price target of $290 as of June 29, 2026. The stock is currently trading at $267.05, reflecting ongoing interest from analysts.
Guggenheim's $290 price target implies 8.60% upside from Natera, Inc.'s ($NTRA) current $267.05 share price.
Natera's stock has fluctuated between $157.43 and $373.07 over the past year, indicating significant volatility as it prepares for its next earnings report on November 5, 2026.
Analysts generally favor Natera, with a consensus recommendation of strong buy based on 23 opinions and a mean price target of $348.02.

Get $NTRA trade alerts by text

We text you when insiders, Congress or big funds trade $NTRA. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Natera, Inc. alert may contain errors. Disclosures

Guggenheim Maintains Buy Rating on Natera

Guggenheim reiterated its buy rating on Natera, Inc. (NasdaqGS: NTRA) on June 29, 2026. The firm set a price target of $290. At the time of the announcement, the stock was trading at $267.05.

Why Guggenheim's Stance Matters

This latest call by Guggenheim reflects confidence in Natera's growth potential. The target price suggests a notable upside from the current trading level. Natera has been actively involved in developing molecular testing services, which positions it well in the healthcare sector.

Analysts Set New Price Targets

Natera has received multiple endorsements from analysts recently. On October 14, JP Morgan maintained an Overweight rating and raised its price target to $460, up from $360. Similarly, Morgan Stanley also maintained its Overweight rating while increasing its target to $435 from $355. Other firms like TD Cowen and Barclays have also maintained bullish ratings, with targets of $480 and $475, respectively. This strong analyst support hints at a positive outlook for Natera as it approaches its next earnings report.

Insider Buying and Selling at Natera, Inc.

Recent insider buying at Natera shows a level of confidence among executives. On June 26, Rowan Chapman purchased 1,674 shares, and Lynch Thomas Jr. bought 1,905 shares. While the exact prices were not disclosed, the timing of these purchases aligns with the company's positive analyst ratings, suggesting insiders believe in the company's potential.

Natera's Business Overview

Natera, Inc. focuses on molecular testing services, including personalized cancer tests and prenatal screening. With a market cap of about $53.4 billion, the company is an innovative player in the diagnostics field. Its diverse testing portfolio includes tests for cancer recurrence and hereditary conditions, which are critical in personalized medicine.

What's Ahead for Natera, Inc.

Investors should keep an eye on Natera's upcoming earnings report scheduled for November 5, 2026. The recent analyst ratings and insider transactions provide a backdrop of optimism as the company prepares to present its financial performance. Remember, Guggenheim's rating reflects positions as of June 29 and may not represent current market conditions.

12-month forecast